Triple-receptor agonist · 10mg formulation
A single precision compound: Retatrutide — the most advanced triple-receptor agonist in metabolic cellular wellness.
Next-generation triple agonist activating GLP-1, GIP, and glucagon receptors for comprehensive metabolic cellular support.
Retatrutide is a next-generation triple agonist compound that targets GLP-1, GIP, and glucagon receptors simultaneously. The RT10 Protocol leverages this triple-action mechanism at a 10mg dose — the entry formulation in the Retatrutide range.
By activating all three receptor pathways, the protocol supports comprehensive metabolic regulation, appetite signalling, energy expenditure, and body composition goals that single or dual agonists cannot address alone.
The RT10 formulation is designed for protocol initiation — allowing the body to adapt to the compound before progressing to higher-dose formulations under expert guidance.
Every Lumeva protocol is manufactured using advanced synthesis techniques within controlled laboratory environments. Carries ≥99.9% purity certification and full batch-specific QA documentation.
Begin with a free consultation to ensure the RT10 Protocol is the right formulation for your metabolic goals.